John V. Brown, MD


John V. Brown, MD, FACOG FACS
attended Medical School at the University of Kansas. He completed an Internship and Residency in Gynecology and Obstetrics at the University of Washington. His fellowship in Gynecologic Oncology was obtained at the University of California, Los Angeles. He is a former Clinical Assistant Professor of Obstetrics and Gynecology at both the University of California, Los Angeles, and at the University of Southern California.  He is a Fellow of the American College of Obstetrics and Gynecology and the American College of Surgeons.

Dr. Jeb Brown has been a terrific advocate of GOA’s charity indigent care program for over 20 years.  Dr. Brown provides the same great care to all his patients.  In addition to doing surgery and consults for free for our poor patients, Dr. Brown has been instrumental in having GOA donate funds to SOS Clinic and other worthy causes.

Download and Print New Patient Forms

CURRICULUM VITAE

John Vincent Brown III, M.D.

Date of Birth:
February 11, 1958

Place of Birth:
Kansas City, Missouri


A. Business Address:

Gynecologic Oncology Associates
351 Hospital Road, Suite 507
Newport Beach, CA 92663
Phone: (949) 642-1361
Fax: (949) 642-1394

URL of Map


B. EDUCATION

Undergraduate:
University of Kansas
B.S., 1980
Major:  Organismal Biology
Cumulative GPA 3.93
Graduation with Distinction

Medical School:
University of Kansas School of Medicine
M.D., 1984
Position in Graduating Class, 24/144

Postgraduate:
Unversity of California at Los Angeles

Training:
School of Medicine
Division of Gynecologic Oncology

Fellowship:  July 1, 1988 to June 30, 1990
University of Washington Medical School
Department of Obstetrics and Gynecology
Residency:  July 1, 1984 – June 30, 1988


C.  MEDICAL LICENSURE

Washington
California


D.  CERTIFICATION

American Association of Gynecologic Laparoscopy
Center of Excellence in Minimally Invasive Gynecologic Surgery
Surgeon Designee (2012)

Diplomate of the American Board of Obstetrics and Gynecology (1991)

Certificate of Special Qualification in Gynecologic Oncology  (1994)

Recertified in Obstetrics and Gynecology and Gynecologic Oncology (1999)

 

E.  PROFESSIONAL BACKGROUND

Academic Appointments

Assistant Clinical Professor

University of California at Los Angeles

School of Medicine

Harbor/UCLA Medical Center

June 25, 1990 – 1999

Assistant Clinical Professor

University of Southern California

School of Medicine

October, 1999—2005

 

Professional Employment
Private Practice specializing in Gynecologic Oncology

Newport Beach, CA

1990-present

 

F.   AWARDS

Summerfield Scholar, 1977

Veta B. Lear Award, (4.0 GPA for Freshman year), 1977

Owl Society (Junior Men’s Honorary Society), 1979

Mortar Board, 1980

Omicron Delta Kappa (Vice President), 1980

Educational Foundation Scholarship, 1980

Phi Kappa Phi, 1980

J. George Moore Award (Best paper by a fellow, Western  Association Gynecologic Oncologists), 1990

 

G.    PROFESSIONAL SOCIETIES

American College of Obstetricians and Gynecologists (Fellow)

Society of Gynecologic Oncologists (Member)

American College of Surgeons (Fellow)

American Society of Clinical Oncologists (Member)

Western Association of Gynecologic Oncologists (Member)

Society of Surgical Oncologists (Member)

International Society of Gynecologic Cancer (Member)

Pacific Coast Obstetrical and Gynecological Society (Member)

 

H.    COMMITTEES/LEADERSHIP

Obstetrics and Gynecology Core Committee, Irvine Medical Center

Society of Gynecologic Oncology Education and Exhibit Ad Hoc Committee:

1997-1999.

Cancer Committee, Hoag Memorial Presbyterian Hospital:  2000-present.

Co-Director, Society of Gynecologic Oncologists Winter Meeting 1999-present

Co-Chair of Society of Gynecologic Oncology Clinical Practice Committee: 2004

Chair of Society of Gynecologic Oncology Clinical Practice Committee: 2005-2008.

Council Member of Society of Gynecologic Oncologists; 2005-2008

Member, Society of Gynecologic Oncology Clinical Practice Committee 2001- present

American College of Surgeons Committee on Applicants: 1998-present.

Member, Society of Gynecologic Oncologists Quality and Outcomes Committee 2010-present

Member, Society of Gynecologic Oncologists Annual Meeting Program Committee, 2010

Obstetrics and Gynecology Core Committee, Hoag Memorial Presbyterian Hospital:  2003-2009.

Gynecologic Cancer Foundation Nominating Committee, 2006

Member, Hoag Memorial Hospital Women’s Health Institute Advisory Council, 2010-

Member, Hoag Memorial Hospital Continuum of Care Task Force, 2010-

 

I.          PUBLICATIONS

Brown JV, Stenchever MA.  Cavernous lymphangioma of the vulva. Obstet Gynecol 1989;73:877-9.

Brown JV, Fu YS, Berek JS.  Ovarian metastases are rare in stage I adenocarcinoma of the cervix. Obstet Gynecol 1990;76:623-6.

Brown JV, Peters WA, Corwin DJ.  Invasive carcinoma after cone biopsy for cervical intraepithelial neoplasia. Gynecol Oncol 1991;40:25-28.

Brown JV, Karlan BY, Greenspoon JS, Rosove MH, Lagasse LD.  Perioperative coagulopathy in patients undergoing primary cytoreduction. Cancer 1993;71:2557-61

Malfetano J, Brown J, Abrams J, Homesley H, Benegno B, Braly P, Bean L, Malta E, Dziem G.  Filgrastim (r-met-HuG-CSF) as an Adjunct to Cyclophosphamide and Carboplatin Chemotherapy in Advanced Ovarian Carcinoma. Proc Am Soc Clin Oncol 1993;12:265.

Micha JP, Rettenmaier MA, Dillman R, Fraser P, Birk C, Brown JV.  Single dose Dexamethasone Taxol premedication.  Gynecol Oncol; 69:122-124, 1998.

Micha JP, Brown JV.  Primary surgical cure of stage III-B cervical carcinoma with adnexal metastasis.  Gynecol Oncol; 71, 317-319, 1998

Micha JP, Rettenmaier MA, Francis L, Willenberg R, Brown JV.  “Medically necessary” panniculectomy to facilitate radical pelvic surgery in morbidly obese patients. Gynecol Oncol; 69:237-242, 1998

Brown JV, Rettenmaier MA, Dillman R, Birk C, Culkin K, Micha JP.  Three hour paclitaxel infusion and carboplatin is an effective outpatient treatment for stage III epithelial ovarian cancer.  Gynecol Oncol; 68:166-168, 1998

Dillman RO, Nayak SK, Johnson D, Brown J, Chico S.  The potential to use short-term cultures of ovarian cancer cells as autologous tumor cell vaccines.  Proc Am Assoc Cancer Res 1997; 38:399, abstract 2676.

Dillman RO, Nayak SK, Brown JV, Mahdavi K, Beutel LD. The feasibility of using short-term cultures of ovarian cancer cells for use as autologous tumor cell vaccines as adjuvant treatment of advanced ovarian cancer. Cancer Biother 1999;14:443-49.

Brown JV, Peters WA, Rettenmaier MA, Karlan BY, Dillman RA, Smith MR, Drescher CW, Micha JP. A phase I trial of a 3-day Topotecan Q 21 days for recurrent epithelial cancers of the ovary, fallopian tube, and peritoneum. Gynecol Oncol 79; 2000.

P Sabbatini, J Brown, Carol Aghajanian, M L Hensley, S Pezzulli, C O’Flaherty, M Lovegren, S Funt, M Warner, P Mitchell, M G Bolton, D Spriggs, B Duggan. A phase I/II study of PG-paclitaxel (CT-2103) in patients (pts) with recurrent ovarian, fallopian tube, or peritoneal cancer.  Proc Am Soc Clin Oncol 2002; abstract 871.

Brown JV, Peters WA, Rettenmaier MA, Dillman RA, Smith MR, Drescher CW, Micha JP. Three Consecutive Day Topotecan is an Active Regimen for Recurrent Epithelial Ovarian Cancer. Gynecol Oncol 2003;88:136-140.

Rettenmaier MA, Brown JV, Micha JP.  Modified vestibulectomy is inadequate treatment for secondary vulvar vestibulitis.  Jnl Gynecol Surg 2003;19(1):13-18.

Micha JP, Goldstein BH, Rettenmaier MA, Mattison J, Graham C, Birk CL, Brown JV.  Pilot Study of Outpatient Paclitaxel, Carboplatin and Gemcitabine for Advanced Stage Epithelial Ovarian, Peritoneal, and Fallopian Tube Epithelial Cancer. Gynecol Oncol 2004;94:719-724

Micha JP, Goldstein BH, Hunter JV, Rettenmaier MA, Brown, JV.  Long-term survival in an Ovarian Cancer Patient with Brain Metastases: A Case Report.  Gynecol Oncol 2004;92:978-980.

Brown JV, Goldstein BH, Rettenmaier MA, Aylward MM, Graham CL, Micha JP.  Laser ablation of surgical margins after excisional partial vulvectomy for VIN:  Effect on recurrence. J Repro Med  2005;50:345-350.

Rettenmaier MA, Goldstein BH, Brown JV, John CR, and Micha JP.  Impact of Gynecologic Oncologists on Referral Patterns and Care of Patients with Uterine Malignancies at a Community Hospital. Jnl Gynecol Surg 2004;20: 57-63.

Micha JP, Goldstein BH, Rettenmaier MA, Brown JV.  Cecal pelvic transposition following total pelvic exenteration.  Gynecol Oncol 2004;94:589-592.

Micha JP, Goldstein BH, Robinson PA, Rettenmaier MA, Brown JV.  Abdominal/Pelvic Coccidioidomycosis.  Gynecol Oncol 2005; 96; 256-258.

Micha JP, Goldstein BH, Mattison JA, Bader KM, Graham C, Rettenmaier MA, Brown JV, Markman M.  Experience with single agent paclitaxel consolidation following primary chemotherapy with carboplatin, paclitaxel, and gemcitabine in advanced ovarian cancer. Gynecol Oncol 2005;96:132-5.

Sabbatini P, Aghajanian C, Dizon D, Anderson S, Duport J, Brown JV, Peters WA, Jacobs A, Mehdi A, Rivkin S, Eisenfeld AJ, Spriggs D. Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.  J Clin Oncol 2004; 22: 4523.

Brown JV, Goldstein BH, Duma CM, Rettenmaier MA, Micha JP.Gamma-Knife

Radiosurgery for the Treatment of Ovarian Cancer Metastatic to the Brain.  Gynecol Oncol 2005; 97; 858-61.

Micha JP, Goldstein BH, Bock BV, Rettenmaier MA, Brown III JV. Spontaneous    Bacterial Peritonitis.   Int J Gynecol Cancer 2006; 16: 908-911.

Micha JP, Goldstein BH, Rettenmaier MA, Brown III JV, John CR, Markman M. Surgery Alone or Surgery with a Combination Radiation or Chemo-Radiation for Management of Patients with Bulky Stage 1B2 Cervical Carcinoma. Intl J Gynecol Cancer 2006; 16: 1-5.

Micha JP, Goldstein BH, Rettenmaier MA, Brown III JV. A Rare Caseof Coccygeal Endometriosis. Obstet Gynecol 2006; 107:1-2.

Rettenmaier MA, Goldstein BH, Brown III JV, Van Horn D, Micha JP.Recurrent gestational trophoblastic disease following persistently normal hCG titers: A rare occurrence. Accepted to the Am J Clin Oncol 2005.

Rettenmaier MA, Goldstein BH, Stallman JM, Brown III JV, Micha JP. GreatlyElevated Serum CA-125 Level in a Patient with a RupturedEndometrioma. J Gynecol Surg 2005; 21: 109-112.

Rettenmaier MA, Goldstein BH, Epstein HD, Brown JV 3rd, Micha JP.  Serous psammocarcinoma of the ovary: An unusual finding.  Gynecol Oncol  2005; 99:510-11.

Micha JP, Goldstein BH, Birk CL, Rettenmaier MA, Brown III JV.  Abraxane in the treatment of ovarian cancer:  The absence of hypersensitivity reactions.  Gynecol Oncol 2006; 100: 437-438.

Brown JV, Goldstein BH, Rettenmaier MA, Michelle MM, Graham CL, Micha JP. Laser Ablation of Surgical Margins After Excisional Partial Vulvectomy for VIN. Obstet Gynecol Surv 2005;60:584-5.

Micha JP, Goldstein BH, Rettenmaier MA, Brown III JV. Pelvic RadiationNecrosis and Osteomyelitis Following Treatment for Advanced CervixCarcinoma. Gynecol Oncol 2006; 101: 349-352.

Rettenmaier MA, Goldstein BH, Stallman JM, Brown III JV Micha JP.Lymphoepithelial carcinoma of the cervix: Review and treatment course. J Gynecol Surg 2006; 21: 185-88.

Micha JP, Goldstein BH, Rettenmaier MA, Brown JV III, Markman M. Surgery alone or surgery with a combination radiation or chemoradiation for management of patients with bulky-stage IB2 cervical carcinoma. Int J Gynecol Cancer 2006; 16: 1-5.

Micha JP, Goldstein BH, Epstein HD, Rettenmaier MA, Brown III JV. Ovarian Cancer Metastatic to the Breast.  Gynecol Oncol 2006;102: 386-390.

Rettenmaier MA, Goldstein BH, Stallman JM, Micha JP, Brown III JV.  Vaginal reconstruction following supra-levator exenteration.  Gynecol Oncol 2006; 102: 397-399.

Micha JP, Goldstein BH, Rettenmaier MA, Brown III JV.  Neo-vagina Reconstruction Utilizing the Bladder and Urethra Following Radical Radiation Therapy.  J Gynecol Surg 2006;22:73-75.

Micha JP, Goldstein BH, Zusman D, Rettenmaier MA, Epstein HD Brown III JV. Malignant Pericardial Effusion Secondary to Ovarian Adenocarcinoma.  J Reprod Med 2007; 52: 971-3.

Rettenmaier MA, Goldstein BH, Haghighi B, Brown III JV, Micha JP. Serous endometrial intraepithelial carcinoma: Diagnosis and clinical management. J Gynecol Surg 2006;22: 69-72.

Micha JP, Goldstein BH, Rettenmaier MA, Brown III JV. A response to Batt in A rare case of precoccygeal endometriosis. (Response to Letter to Editor). Obstets Gynecol 2006; 108:213-214.

Micha JP, Goldstein BH, Rettenmaier MA, Oglevie S, Lindsay SF, Haskell R, Brown JV III. Subclavian arterial puncture repair with Angio-Seal deployment. Gynecol  Oncol 2007; 104: 761-3.

Micha JP, Goldstein BH, Epstein HD, Rettenmaier MA, Doering R, Brown III JV.A Precarious Case of Multiple Enlarged Arteriovenous Malformations in the Uterus. J Gynecol Surg 2007; 23: 23-29.

Micha JP, Goldstein BH, Rettenmaier MA, Genesen M, Graham CL, Bader K,  Lopez KL, Nickle M, Brown JV. A Phase II Study of Outpatient First Line Paclitaxel, Carboplatin and Bevacizumab for Advanced Stage Epithelial Ovarian, Peritoneal, and  Fallopian Tube Cancer. Intl J Gynecol Cancer 2007;17: 771-6.

Brown JV, Goldstein BH, Lopez K, Rettenmaier MA, Graham CL, Micha JP.A Phase II, Multi-Center Trial of Weekly Topotecan In Patients With Recurrent Platinum Sensitive Epithelial Cancers of the Ovary, Fallopian Tube, and Peritoneum. Intl J Gynecol Cancer 2008; 18:249-54.

Micha JP, Goldstein BH, Brown JV, Birk C, Van Horn D, Rettenmaier MA. Tuberculosis Mimicking Cervical Carcinoma. Euro J Gynaecol Oncol 2007; 28: 316-318.

Micha JP, Goldstein BH, Rettenmaier MA, Tinnerman-Minailo E, Brown JV, McCllellan S, Bock BV. Recurrent Vulvar Lymphangitis Cured with Vulvectomy in a Cervical Carcinoma Patient.  J Reprod Med 2008; 53: 299-301.

Micha JP, Goldstein BH, Ellison D, , Brown JV, Rettenmaier MA. A Rare Case of Low-Grade Pelvic Masses with Spindle Cell and Fibroblastic Proliferation. J Med Case Reports 2007; 1: 16-19.

Micha JP, Goldstein BH, Brown JV, Clark M, Hu JC, Rettenmaier MA. Successful Management of Acute Renal Failure with Vaginal Pessary. A Case Report. Gynecol Surgery 2008; 5: 49-51.

Micha JP, Rettenmaier MA, Kistler M, Epstein HD, Lim J, Brown JV, Goldstein BH.     Retroperitoneal Schwannoma Presenting as a Gynecologic Mass: A Rare Case Report.  Gynecol Surg  2007; 23: 157-62.

Brown JV, Epstein HD, Kim R, Micha JP, Rettenmaier MA, Mattison J, Goldstein   Rapid Manifestation of CNS Metastatic disease in a Cervical Carcinoma Patient: A Case Report. Oncology 2007; 73: 273-276.

Micha JP, Brown JV, Sheffer EC, Chan K, Rettenmaier MA, Goldstein BH. Sarcoidosis Imitating Metastatic Cervical Cancer.  Arch Gynecol Obstets 2008;277:441-3.

Brown III JV, Micha JP, Asrat T, Epstein HD, Oglevie S, Rettenmaier MA, Goldstein BH.Contemporary Diagnosis and Management of a Uterine Arteriovenous Malformation: A  Case Report. Obstet Gynecol. 2008 Aug;112(2 Pt 2):467-70.

Rettenmaier MA, Brown III JV, Micha JP, Heinemann FS, Goldstein BH.Cerebral Nocardia Masquerading as Metastatic CNS Disease in an Endometrial Cancer     Patient. Accepted to Euro J Gynaecol Oncol 2008.

Micha JP, Goldstein BH, Rettenmaier MA, Brown JV, John CR, Markman M. The  Clinical Utility of CA-125 for Maintenance Therapy in the Treatment of Advanced Stage   Ovarian Carcinoma. Int J Gynecol Cancer. 2009 Mar-Apr;19(2):239-41.

Brown III JV, Epstein HD, Mattison JN, Micha JP, Rettenmaier MA, Goldstein BH. Occult  Fallopian Tube Cancer in a BRCA-1 Breast Cancer Patient: A Case Report. J Minim Invasive Gynecol 2008; 15:749-51.

Goldstein BH, Birk CL, Van Houten M, Veve R, Brown JV, Rettenmaier MA, Micha JP.Ovarian cancer and late onset paraneoplastic cerebellar degeneration:A Case Report. Arch Gynecol Obstet.  2009;280:99-101.

Chalas E, Brown JV, Cliby W. NSQIP—The new frontier?.  Gynecol Oncol 2008;111(2):163-5.

Micha JP, Graham CL, Rettenmaier MA, Brown JV 3rd, Goldstein BH.New perspectives in clinical research: the Women’s Cancer Research Foundation’sexperience. Perspect Health Inf Manag 2009;6:1-12.

Rettenmaier MA, Brown III JV, Micha JP, Heinemann FS, Goldstein BH.   Marlex Mesh Mimicking an Adnexal Malignancy. Hernia 2009; 13: 221-223.

Rettenmaier MA, Lopez K, Graham CL, Brown JV, John CR, Micha JP, Goldstein BH.  RealHand High Dexterity Instruments for the Treatment of Stage I Uterine Malignancy. JSLS 2009; 13:27-31.

Zekry N, Rettenmaier MA, Abaid LN, John CR, Micha JP, Brown JV, Goldstein BH.  Perivascular epithelioid cell neoplasms:  A systematic review of prognostic factors. Accepted for publication.  J Minim Invasive Gynecol 2009; 16:527-32.

Rettenmaier MA, Abaid LN, Hu JC, Brown JV, Micha JP, Goldstein BH. Delayed staple erosion into the bladder after removal of a benign ovarian mass.  J Minim Invasive Gynecol 2009; 16:491-492.

Rettenmaier MA, Zekry N, Chang M, Palmer A, Brown III JV, Micha JP, Goldstein BH.  A heavily pigmented vaginal perivascular epithelioid cell neoplasm.  J Obstet Gynecol 2009; 29: 676 -77.

Rettenmaier MA, Lopez K, Abaid LN, Brown III JV, Micha JP, Goldstein BH.  Borderline ovarian tumors and extended patient follow up:  An individual institution’s experience. J. Surg. Oncol. 2009;00:1–4.

Rettenmaier MA, Abaid LN, Erwin MR, John CR, Micha JP, Brown JV 3rd, Goldstein BH.  A retrospective Review of the GelPort System in Single-Port Access Pelvic Surgery.  J Minim Invasive Gynecol 2009; 16:743-7.

Rettenmaier MA, Lopez K, Abaid LN, Brown JV, Micha JP, Goldstein BH.Borderline Ovarian Tumors and Extended Patient Follow-up:An Individual Institution’s Experience. J Surg Oncol 2009; 101:18-21.

Rettenmaier MA, Abaid LN, Brown JV, Micha JP, Goldstein BH.  CHemotehrapy and patient co-morbidity in ventral site hernia development.  J Gynecol Oncol 2009;20:246-50.

Brown JV III, Epstein HD, Chang M, Goldstein BH. Sarcoidosis Presenting as an Intra-Peritoneal Mass.  Case Rep Oncol 2010;3:9-13.

Abaid LN, Lopez K, Micha JP, Rettenmaier MA, Brown JV, Goldstein BH.  Absence of bowel perforation and reasonable hypertension rates with bevacizumab in the treatment of advanced stage ovarian carcinoma. Eur J Gynaec Oncol 2010: Accepted for publication.

Brown JV III, Micha JP, Rettenmaier MA, Abaid LN, Lopez KL, Goldstein BH.  A pilot study evaluating a novel regimen comprised of carboplatin, paclitaxel and bevacizumab for advanced stage ovarian carcinoma. Int J Gynecol Cancer 2010; 20: 1125-1131.

Abaid LN, Goldstein BH, Micha JP, Rettenmaier MA, Brown JV, Markman M.Improved Overall Survival with 12-Cycles of Single Agent Paclitaxel Maintenance Therapy Following a Complete Response to Induction Chemotherapy in Advanced Ovarian Carcinoma.  Oncol 2010;78:389-393.

Rettenmaier CR, Rettenmaier NB, Wojciechowski T, Abaid LN, Brown III JV, Micha JP, Goldstein BH.  The Utility of Routine Follow-up Procedures in the Surveillance of Uterine Carcinoma: A 20-year   institutional review. Accepted to Oncol 2010.

Rettenmaier NB, Rettenmaier CR, , Wojciechowski T, Abaid LN, Brown III JV, Micha JP, Goldstein BH.  The Utility and Cost of Routine Follow-up Procedures in the Surveillance of Ovarian and Primary Peritoneal Carcinoma: A 16-year Institutional Review. Br J Cancer  2010;103L1657-62.

Abaid LN, Goldstein BH, Lopez KL, Micha JP, Brown JV, Rettenmaier MA, Markman M. The Prognostic Significance of Optimal Debulking in the Setting of a Complete Clinical Response for Advanced Ovarian Carcinoma Patients Receiving Maintenance Chemotherapy. Arch Gynecol Obstet 2011; 283: 1127-1131.

Mendivil AA, Abaid LN, Epstein HD, Rettenmaier MA, Brown JV III, Micha JP, Wabe MA, Goldstein BH. Paget’s Disease of the Vulva: A Clinicopathologic Institutional Review. Int J Clin Oncol 2012; 17:569-74.

Mendivil A, Rettenmaier MA, Cox C, Abaid LA, Brown JV, Micha JP, Lopez KL, Goldstein BH. Acute and Delayed Complications from Surgery and Adjuvant Radiotherapy in the Treatment of High Risk Endometrial and Cervical Cancer. 2011 Oncology, 81:79-83.

Abaid LN, Rettenmaier MA, Brown III JV, Micha JP, Mendivil AA, Wabe MA, Goldstein BH. Sequential chemotherapy and radiotherapy as sandwich therapy for the treatment of high risk endometrial cancer.  J Gynecol Oncol 2012; 23: 22-27.

Rettenmaier MA, Mendivil AA, Brown JV III, Abaid LN, Micha JP, Goldstein BH. Same Day Discharge in Clinical Stage 1 Endometrial Cancer Patients Treated with Total Laparoscopic Hysterectomy, Bilateral Salpingoophorectomy and Bilateral Pelvic Lymphadenectomy. Oncol 2012;82:321-326

Mendivil AA, Abaid L, Epstein HD, Rettenmaier MA, Brown JV 3rd, Micha JP, Wabe MA, Goldstein BH. Paget’s disease of the vulva: a clinicopathologic institutional review. Int J Clin Oncol 2012; 17:569-74.

Abaid LN, Cupp JS, Brown JV, Goldstein BH. Primary Small Cell Neuroendocrine Carcinoma of the Endometrium. Oncol 2012; 5:439–443.

Brown JV III, Stallman JM, Wong H, Duma CM, Goldstein BH.   Spinal Epidural Metastasis in an Endometrial Cancer Patient.  Gynecol Oncol 2012; 2: 20-22.

Brown III JV, Mills MD, Wong H, Goldstein BH. Large Volume Cervical Varix Bleeding in a Gravid Patient. Gynecol Oncol 2013; 4: 20–22.

Mendivil AA, Micha JP, Brown JV 3rd, Rettenmaier MA, Abaid LN, Lopez KL, Goldstein BH. Increased incidence of severe gastrointestinal events with first-line Paclitaxel, Carboplatin, and Vorinostat chemotherapy for advanced-stage epithelial ovarian, primary peritoneal, and fallopian tube cancer. Int J Gynecol Cancer 2013;23:533-9.

Micha JP, Brown JV, Rettenmaier MA, Abaid LN, Mendivil AA, Lopez KI, Goldstein BH. Pegfilgrastim safely administered on the same day as dose-dense chemotherapy for patients with advanced-stage ovarian cancer. Clin Oncol 2013; Feb (letter).

Abaid LN, Micha JP, Rettenmaier MA, Brown JV, Mendivil AA, Lopez KL, Goldstein BH. A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma. Cancer Chemother Pharmacol 2013;72:101-107.

Brown JV III, Heinemann FS, Laflamme LA, Goldstein BH. An Unusual Case Involving a Uterine Serous Carcinoma with an Intercurrent Lymphatic PEComa. Int J Clin Oncol 2012; 2: 157-160.

Abaid LN, Thomas RH, Epstein HD, Goldstein BH. Clostridial Abdominal Gas Gangrene Masquerading as a Bowel Perforation in an Advanced Stage Ovarian Cancer Patient. Infect 2013; 4: 885-888

Mendivil AA, Brown III JV, Abaid LN, Rettenmaier MA, Micha JP, Wabe MA, Goldstein BH. Robotic-Assisted Surgery for the Treatment of Pelvic Masses in Pregnant Patients: A Series of Four Cases and Literature Review.J Robot Surg 2013; 7: 333–337. Care 2013; 2: 124.

Rettenmaier CR, Rettenmaier NB, Abaid LN, Brown JV, Micha JP, Mendivil AA, Wojciechowski T, Goldstein BH, Markman M. The Incidence of Genitourinary and Gastrointestinal Complications in Open and Endoscopic Gynecologic Cancer Surgery. Oncology 2014; 86:303-307

Rettenmaier MA, Abaid LN, Brown JV 3rd, Mendivil AA, Micha JP, Goldstein BH. The incidence of postprandial nausea and nutritional regression in gynecologic cancer patients following intestinal surgery: A retrospective cohort study. Int J Surg 2014; 12: 783-787.

Brown JV, Mendivil AA, Abaid LN, Rettenmaier MA, Micha JP, Wabe MA, Goldstein BH. The Safety and Feasibility of Robotic Lymph Node Staging in Early-Stage Ovarian Cancer. Int J Gynecol Cancer 24(8) 2014.

Brown JV, Rausei-Mills V, Crum CP, Goldstein BH. Management of a Female Adnexal Tumor of Probable Wolffian Origin Complicated by Intercurrent Disseminated Intravascular Coagulation. Clin Ovarian and Other Gyn Cancer. Dec 2013 58-61.

J. PRESENTATIONS

Brown JV, Karlan BY, Lagasse LD.  Improved cytoreduction with the Ultrasonic Surgical Aspirator. Western Association of Gynecologic Oncologists. May, 1989.

Brown JV, Fu YS, Berek JS.  Ovarian metastases are rare in stage I adenocarcinoma of the cervix. Western Association of Gynecologic Oncologists. June, 1990.

Brown JV, Karlan BY, Rosove MH, Leuchter R, Futoran R, Lagasse LD.  Perioperative coagulopathy in patients undergoing primary cytoreduction. Western Association of Gynecologic Oncologists. June, 1991.

Brown JV, Rettenmaier MA, Micha JP. A pilot study of oral etoposide for recurrent or persistent ovarian cancer. Western Association of Gynecologic Oncologists. June, 1992.

Brown JV, Rettenmaier MA, Micha JP, Tullio R, Burke C. Taxol and Carboplatin is an effective outpatient regimen for advanced ovarian cancer. Western Association of Gynecologic Oncologists. June, 1995.

Dillman RO, Nayak SK, Johnson D, Brown J, and Chico S.  The potential to use short-term cultures of ovarian cancer  autologous tumor cell vaccines.  American Asssociation for Cancer Research. March, 1997.

Brown JV, Peters WA, Rettenmaier MA, Karlan BY, Dillman RA, Smith MR, Drescher CW, Micha JP. A phase I trial of a 3-day Topotecan Q 21 days for recurrent epithelial cancers of the ovary, fallopian tube, and peritoneum. Society of Gynecologic Oncologists. February, 2000.

Brown JV, Peters WA, Rettenmaier MA, Dillman RA, Smith MR, Drescher CW, Micha JP. Three Consecutive Day Topotecan is an Active Regimen for Recurrent Epithelial Ovarian Cancer.  Society of Gynecologic Oncologists. March, 2002.

P Sabbatini, J Brown, Carol Aghajanian, M L Hensley, S Pezzulli, C O’Flaherty, M Lovegren, S Funt, M Warner, P Mitchell, M G Bolton, D Spriggs, B Duggan. A phase I/II study of PG-paclitaxel (CT-2103) in patients (pts) with recurrent ovarian, fallopian tube, or peritoneal cancer.  American Society of Clinical Oncologists.  May, 2002.

Sabbatini P, Brown J, Bolton M.  Phase I/II study of PG-paclitaxel (CT 2103) in patients with recurrent ovarian cancer.  European Spring Oncology Conference. June, 2002.

Sabbatini P, Brown J, Peters WA, Andrew J, Mehdi A, Crozier MA, Rivkin S, Bolton MG. Phase I/II study of CT-2103 (Xyotax) in patients with recurrent ovarian cancer.  Memorial Sloan-Kettering Cancer Center, New York, NY; Gynecologic Oncology Associates, Newport Beach, CA; Pacific Gynecology Specialists; Virginia Mason Medical Center; Stockton Hematology Oncology Medical Group; Southwest Regional Cancer Cancer Center; Swedish Medical Center and Tumor Institute; Cell Therapeutics, Inc, Seattle, WA. European Organisation for Research and Treatment of Cancer (EORTC).  November, 2002.

Peters WA, Brown JV, Rivkin S, Bolton MG, Sabbatini P.  Phase I/II Study of CT-2103 (Xyotax) in Patients with Recurrent Ovarian Cancer.  Society of Gynecologic Oncologists.  February, 2003.

Brown JV, Goldstein BH, Rettenmaier MA, Aylward MM, Graham CL, Micha JP.  Laser ablation of surgical margins following excisional partial vulvectomy for vulvar intraepithelial neoplasia may decrease recurrences.  Pacific Coast Obstetrical and Gynecological Society.  September, 2003.

Micha, JP, Goldstein BH, Rettenmaier, MA, Mattison J, Graham CL, Birk CL,
and Brown JV. Pilot study of outpatient paclitaxel, carboplatin and
gemcitabine for advanced stage epithelial ovarian, peritoneal, and fallopian
tube epithelial cancer. Eli Lilly Investigators Meeting March 2003, Phoenix, AZ.

Micha, JP, Goldstein BH, Rettenmaier, MA, Mattison J, Graham CL, Birk CL,and Brown JV. Paclitaxel, carboplatin and gemcitabine for treatment of advanced stage ovarian cancer. Eli Lilly Investigators Meeting April 2004, Phoenix, AZ.

Micha JP, Goldstein BH, Rettenmaier MA, Bader K, Graham C, Lopez K, Nickle M, Genesen M, Brown JV III.  Pilot Study of Outpatient Paclitaxel, Carboplatin and Bevacizumab for Advanced Stage Epithelial Ovarian, Peritoneal, and Fallopian Tube Cancer.  International Gynecologic Cancer Society Meeting, Santa Monica, CA; October 2006.

Abaid LN, Micha JP, Rettenmaier MA, Brown JV III, Mendivil AA, Lopez KL, Goldstein BH. A phase II study of modified dose-dense paclitaxel and every 4 week carboplatin for the treatment of advanced stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma. Society of Gynecologic Oncology 42nd Annual Meeting, Austin TX, March 24-27, 2012.

Mendivil AA, Rettenmaier MA, Abaid LN, Brown JV III, Micha JP, Lopez KL, Goldstein BH. A Comparison of Open Surgery, Robotic-Assisted Surgery and Conventional Laparoscopic Surgery in the Treatment of Morbidly Obese Endometrial Cancer Patients. ESJO Annual Meeting; October 2013: Liverpool, UK.

K.     RESEARCH GRANTS.

Bristol Myers Squibb
Principle Investigator
Phase I/II study of intravenous paclitaxel and carboplatin in patients with stage III/IV epithelial ovarian cancer (Three hour paclitaxel infusion)

Principle Investigator
Phase II study of intravenous paclitaxel and carboplatin in patients with stage III/IV epithelial ovarian cancer (One hour paclitaxel infusion)

Amgen
Co-Principle Investigator
Filgrastim (r-met-HuG-CSF) as an Adjunct to Cyclophosphamide and Carboplatin Chemotherapy in Advanced Ovarian Carcinoma

Smith Kline Beecham
Principle Investigator
A phase I/II trial of topotecan in patients with platinum and taxane refractory epithelial ovarian cancer

Principle Investigator
A phase II trial of three day topotecan q 21 days for recurrent epithelial carcinomas of the ovary, fallopian tube, and peritoneum.

Eli Lilly
Sub – Investigator
Phase II Trial of Intravenous Taxol, Carboplatin, and Gemzar in Patients With Stage III/IV Epithelial Ovarian Cancer, Stage III/IV Fallopian Tube Epithelial Cancer, Stage III/IV Endometrial Adenocarcinoma, Stage III/IV Malignant Primary Peritoneal Mesothelioma, and Stage III/IV Peritoneal Cancer

Eli Lilly
Principle Investigator
A Phase II Study of Gemcitabine and Carboplatin in Patients with Advanced, Persistent, or Recurrent Carcinoma of the Cervix

Ortho Biotech
Principle Investigator
A Phase II Trial of Doxil and Carboplatin for the Treatment of Advanced, Recurrent, or Persistent Endometrial Carcinoma

Cellpath
Sub – Investigator
A Phase II Trial of CP4071 (Digitoxin) In Patients With Recurrent Epithelial Mullerian Adenocarcinoma

Altarex
Sub – Investigator
A randomized, double-blind, placebo-controlled, phase IIB study of the safety and efficacy of OvaRex (MAb-B43.13) in ovarian cancer patients with an elevated serum CA-125 but without other evidence of disease

Altarex
Sub – Investigator
A multi-center clinical trial of intravenous OvaRex (MAb-B43.13) as post-chemotherapy consolidation for ovarian, tubal and peritoneal carcinoma

Atairgin Technologies, Inc.
Sub – Investigator
A clinical protocol to evaluate the role of lysophosphatidic acid as an aid in the differential diagnosis of ovarian cancer in women scheduled for surgery with a pelvic mass or a suspected ovarian malignancy

Atairgin Technologies, Inc.
Sub – Investigator
A protocol to characterize lysophosphatidic acid assay levels in women not suspected of ovarian cancer

Eli Lilly
Sub – Investigator
A Randomized Phase III Trial of Gemzar versus Doxil with Crossover Treatment Option for Patients with Platinum-Resistant Ovarian, Fallopian Tube, Peritoneal Cancer.

GlaxoSmithKline
Principle Investigator
A Phase II, Multi-Center Trial of Weekly Topotecan in Patients With Recurrent Platinum Sensitive Epithelial Cancers of the Ovary, Fallopian Tube, and Peritoneum

The ANA Study Group
Sub – Investigator
The ANC Study Group Registry: A Prospective Study of Neutropenic Complications

Online Collaborative Oncology Group (OCOG)
Sub – Investigator
A Randomized, Open-Label Study to Assess Time to Hemoglobin Response of a Front Load Dosing Regimen for Darbepoetin Alfa Compared to a Weekly Dose Regimen for Recombinant Human Erythropoietin in Patients with Non-Myeloid Malignancies Receiving Chemotherapy

Unither
Sub – Investigator
A Double Blind, Placebo-Controlled, Multicenter Clinical Trial Of Intravenous OvaRex Mab-B43.13 As Post-Chemotherapy Consolidation For Epithelial Carcinoma Of Ovarian, Tubal Or Peritoneal Origin

Cell Therapeutics
Site Principal Investigator
A phase I/II study of PG-paclitaxel (CT-2103) in patients (pts) with recurrent ovarian, fallopian tube, or peritoneal cancer

Telik
Sub – Investigator
Phase 3 Randomized Study of TLK286 versus Doxil/Caelyx or Hycamptin as Third-Line Therapy in Platinum Refractory or resistant Ovarian Cancer

Cell Therapeutics
Principle Investigator
CT-2103/Carboplatin for Patients with Newly Diagnosed Stage III or IV Ovarian or Primary Peritoneal Cancer: A Phase II Study

Revised 11/14/10